Skip to main content

Table 2 Comparison of the main adverse events between the two groups

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

 

CMBs group n = 110

non-CMBs group n = 122

t or χ2

P value

Event-free time (months)

21.4 ± 12.7

23.4 ± 14.0

−1.101

0.272

CH events (%)

18 (16.4)

13 (10.7)

1.628

0.202

All-cause death (%)

14 (12.7)

13 (10.7)

0.241

0.623